Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.
about
Current and emerging strategies for the prevention of graft-versus-host diseaseAdvances in predicting acute GVHDEndpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statementCurrent and future approaches for control of graft-versus-host disease.The biology of graft-versus-host disease: experimental systems instructing clinical practice.Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials.Pathogenesis and management of graft-versus-host disease.Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation.Recent advances in the management of graft-versus-host disease.Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.Tumor necrosis factor is critical for cytolytic T cell activity against allospecific hepatocytes and splenic targets in major histocompatibility complex class I disparate graft versus host disease.Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids.Management of acute graft-versus-host disease in children.Unsuccessful treatment of four patients with acute graft-vs-host disease after liver transplantation.First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.Have we improved in preventing and treating acute graft-versus-host disease?Implications of TNF-α in the pathogenesis and management of GVHDProteasome inhibition and allogeneic hematopoietic stem cell transplantation: a reviewCombination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival.Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantationPlasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients.A biomarker panel for acute graft-versus-host diseaseAdvances in the treatment of acute graft-versus-host disease.Biomarker Panel for Chronic Graft-Versus-Host Disease.Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials NetworkNonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease.Acute graft-versus-host disease: from the bench to the bedside.Emerging drugs for acute graft-versus-host disease.Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.Acute graft-versus-host disease: new treatment strategies.Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.Progress and prospects: graft-versus-host disease.Suicide gene therapy for graft-versus-host disease.Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.
P2860
Q27016541-EA8791A8-D678-4B1E-9AF4-FCFE422768ECQ27021123-41FBD9FB-B6DD-461F-8DE5-745A1D19FCEBQ33622648-36B3E3FD-1970-4F65-8D29-C9355236B5F6Q33642625-04868437-B612-4411-B624-396458E8BC4DQ33917175-9D18BDDF-FC58-4F9C-91BD-CA90647AD1B3Q33971524-9F713874-6EE2-415E-9F04-8764A2C3BB34Q34077479-9BC3B185-1E10-4F61-AE16-0A76AC19915BQ34093615-3CE3F529-4E3B-4F2A-A28A-C68E7A19FFBEQ34184622-14BEBAD6-849E-4C22-BEB7-D48FB6D2E5FBQ34428890-C492D5FD-00E2-4D41-B6A0-D0C318494DF9Q34487408-8FDAED97-452B-4705-81C3-BFDEA18AFB99Q34607576-D3550D0E-7FDF-4C99-B9F6-4BF620E406CFQ34875248-21E1385C-0963-472C-9F54-C4A275E1CDB4Q35193740-07C18688-E98F-479E-A62F-F6FFEF837A36Q35583009-BF413EC2-D83B-4234-B6E4-6E50040ED3FEQ35653617-57AABF84-284D-4A13-83AB-53C75AA68B1FQ36113205-B6D79581-060F-4EB9-B7E6-31952BC9A417Q36203692-3EA60F06-EEB0-459F-8783-6D5E221F5F26Q36370782-90477C0E-F0F0-43BA-BEC8-838919902024Q36408216-53294096-61C6-4B2C-9285-1A0996FD73EAQ36821646-2D0530A1-2939-44DE-9890-9BDE2F28CA1DQ36835126-CD4EFB3F-2090-4D75-85F4-A828FCBBDA17Q36868082-C4DCD754-B151-431F-B9D8-BBDB1601DA2EQ36891433-3DAE6BCB-5352-4330-BA0C-E1C9037933C8Q36961081-03C860EC-58D2-4494-8441-D204DA6AD7EEQ37041904-B20CE6EB-0784-40B5-B216-CBCE258E582BQ37191057-4FBF2D72-30E8-422A-98DE-28A6C7559A44Q37234820-A4E2B866-C6D7-4FC1-85E6-43FFA652AF97Q37268948-6DFD9DFD-5CBF-4E24-AB56-8B4BC5B8E72DQ37414672-56C4439B-0F74-44EE-8F96-5B4E62C2CFB7Q37420496-908DCADB-8DAA-48CD-8DE9-BF4E3C98EE8BQ37515433-B363FBCD-35B9-4BA1-878C-89FCE6F5BA2EQ37535273-1657F525-98E0-4E06-8F19-630C8451B0C6Q37610714-7CACBE53-A000-4EA4-A30D-31EEDC6B7846Q37621636-8A4726E5-9A24-4A6F-B6F3-6272D9B0F8ECQ37635642-8BF03796-A07B-4B0B-A5A6-48EB41F21662Q37761297-7B0346C1-E6BE-4BFD-85E5-EB1FDDD1BEFCQ37773293-1C2EEF14-CD55-4F0B-A31E-117AA39C665DQ37810286-CA44C831-76BB-4BC3-9C34-940215B53E8DQ37851519-5BB01AB6-62EC-4D42-9DF8-ACB1D37D067C
P2860
Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Etanercept plus methylpredniso ...... ute graft-versus-host disease.
@ast
Etanercept plus methylpredniso ...... ute graft-versus-host disease.
@en
type
label
Etanercept plus methylpredniso ...... ute graft-versus-host disease.
@ast
Etanercept plus methylpredniso ...... ute graft-versus-host disease.
@en
prefLabel
Etanercept plus methylpredniso ...... ute graft-versus-host disease.
@ast
Etanercept plus methylpredniso ...... ute graft-versus-host disease.
@en
P2093
P2860
P1433
P1476
Etanercept plus methylpredniso ...... ute graft-versus-host disease.
@en
P2093
Carrie L Kitko
Daniel Bickley
Dawn Jones
Gregory Yanik
James L M Ferrara
John E Levine
Oleg Krijanovski
Pavan Reddy
Raymond J Hutchinson
Shin Mineishi
P2860
P304
P356
10.1182/BLOOD-2007-09-112987
P407
P577
2007-11-27T00:00:00Z